underscored by the finding that B7-1/B7-2 -/-BM was less likely than wild-type BM to be rejected. Collectively, these data offer new insight into the mechanism of alloresponses regulating GVHD and BM rejection.
Introduction
Cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs) are synthetic oligodeoxynucleotides with unmethylated DNA sequences that mimic viral and bacterial DNA and are recognized by TLR9, a pattern-recognition receptor, expressed in certain innate immune cells, including dendritic cell (DC) subsets, macrophages, monocytes, neutrophils, and NK cells and also in activated CD4 + T cells and B cells [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . CpG ODNs are known to trigger innate immune activation resulting in the expression of costimulatory molecules, resistance to apoptosis and the secretion of Th1-promoting chemokines and cytokines including Macrophage Inflammatory Protein-1, IFN-inducible protein-10 and other IFN-inducible proteins 9, [18] [19] [20] [21] [22] [23] [24] . This innate immune activation typically is followed by the generation of potent adaptive immune responses.
Immunostimulatory CpG ODNs have been shown to protect against a broad range of viruses, bacteria, intracellular parasites, prions, immune disorders and tumors in numerous animal and human models of disease (reviewed in 9, 25 ).
Our previous studies showed that CpG ODNs were highly effective in reducing tumor-related mortality in murine recipients of syngeneic bone marrow transplants and acute myeloid leukemia 26 . However, although CpG ODNs increased the graft-versusleukemia effect of delayed lymphocyte infusion (DLI) in allogeneic bone marrow transplantation (BMT) recipients resulting in enhanced survival, CpG ODNs also increased DLI-induced GVHD as indicated by clinical appearance and weight curves 26 .
The present study was undertaken to directly determine the effects of CpG ODNs on donor anti-host alloresponses that can culminate in GVHD and also on host anti-donor only.
For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From alloresponses that can culminate in allogeneic BM graft rejection. We found that CpG ODNs, administered at the time of transplantation, accelerated GVHD lethality by TLR9 ligation of host APCs. In addition, we demonstrated that CpG ODNs promoted allogeneic BM rejection by TLR9 ligation of donor BM APCs. CpG ODN-mediated BM rejection occurred independently of host TLR9 ligation. An important and unexpected result of these studies was the finding that donor BM APCs modulate the strength of the rejection process. These data give new insight into the mechanisms of GVHD and allogeneic BM rejection and suggest that donor BM APCs may be a potential therapeutic target for the enhancement of alloengraftment in BMT. given ip on d0 and d7. To obtain optimal images, mice were killed and dissected for imaging but no tissue processing was required. Three to four mice per group were examined at day 14. Images were taken with a Retiga Exi color camera and QCapture software, (Qimaging, Burnaby, B.C., Canada) mounted onto a Leica MZFLIII stereomicroscope using a GFP2 or a GFP/dsRED-bandpass filter and a 1.0X transfer lens (Leica Microsystems, Bannockburn, IL). Zoom factors from 3.5-10x were used for imaging d1-14 (3.5x for inguinal LN, ileum, peyer patch, and skin, 7.0x for liver, spleen and kidney, 10.0x for lung). Exposure times were optimized for each organ and identical 
Results

CpG ODNs given at the time of BMT markedly accelerate GVHD-induced mortality.
Numerous studies indicate that immunostimulatory CpG ODNs confer potent antiinfectious and anti-tumor properties (reviewed in 9, 25 ). Although allogeneic BMT recipients are at significant risk of infectious complications and tumor relapse, and therefore might be expected to benefit from CpG ODNs, we hypothesized that CpG Lethal irradiation creates a proinflammatory milieu that is known to contribute to optimal GVHD generation and lethality 29 . CpG ODN-mediated acceleration of GVHD only.
For personal use at PENN STATE UNIVERSITY on February 22, 2013. bloodjournal.hematologylibrary.org From was not dependent upon irradiation as CpG ODNs accelerated mortality in non-irradiated BALB/c SCID recipients of B6 T cells ( Figure 1C , p < 0.05 for both cell doses).
Collectively, these data indicate that CpG ODNs administered early after BMT markedly accelerate GVHD lethality in the presence or absence of radiation-induced injury and in several MHC-disparate donor-recipient strain combinations. Figure 3C ). Of special note, TLR9 -/-and MyD88 -/-mice were not resistant to lethal GVHD.
CpG ODNs increase effector T cell number in lymphoid
Previously, we reported that splenocytes exposed to CpG ODN in vitro released proinflammatory cytokines including IL-6, IL-12p70 and IFNγ 26 . To determine whether CpG ODN-induced GVHD was dependent upon specific host proinflammatory cytokine production, a series of experiments was performed using B6 allogeneic recipients deficient in proinflammatory cytokine production. Whereas B6 IL-6 -/-or B6 IL12p40 For Figure 4E ). At a lower spleen dose, CpG ODN significantly increased the mortality rate in NK-depleted mice from 0% to 63% (p = .005, Figure 4F ). Collectively, these data indicate that CpG ODNs accelerate GVHD and increase GVHD mortality by TLR9 ligation of host APCs in a host IFNγ-dependent, NK cell-independent fashion.
In addition to TLR9 agonists, TLR7 and TLR8 agonists have been developed to target a range of diseases including cancers, infections, asthma, and allergies, and to serve as potent vaccine adjuvants [32] [33] [34] [35] [36] [37] [38] [39] [40] . Like TLR9, TLR7 and TLR8 are located in the intracellular endosomal compartment of innate immune cells with highest expression in plasmacytoid dendritic cells, a DC subset that produces large amounts of type I IFN in response to viral infections (reviewed in 36, 37, 41 ). To determine the effect of other TLR agonists on GVHD, 3M-011, a potent TLR7/8 agonist found to be protective against influenza virus in rats 27 , was administered to B6 recipients of BALB/c BM and a low splenocyte dose.
Similar to TLR9 ligation by CpG ODNs, 3M-011 increased the GVHD mortality rate from 0% to 50% (p = .006, Figure 4G ). Given the critical role of host TLR9 signaling and IFNγ production on GVHD acceleration, we considered two possibilities. The explanation we favored was that TLR9
signaling of host cells was required for graft rejection but that these effects were not mediated via IFNγ, IL-12p40 or IL-6 production. The alternative and seemingly less likely explanation was that TLR9 signaling was mediating rejection via effects on donor 
Discussion
CpG ODNs have demonstrated efficacy in numerous animal models of infectious agents and tumors (reviewed in 9, 25 ). We showed that although beneficial for increased antitumor effects in syngeneic BMT, CpG ODNs increased the GVL effect of DLI at the risk of increased GVHD in allogeneic BMT 26 . Data presented here directly demonstrate that a TLR9 agonistic CpG ODN administered at the time of allogeneic BMT, increased donor anti-host and host anti-donor T cell responses resulting in increased GVHD and increased rates of donor BM rejection, respectively. Similarly, a TLR7/8 agonist also increased GVHD mortality and promoted donor BM rejection indicating that these findings were not unique to TLR9 stimulation. These data counsel caution in the use of TLR agonists in the early period following allogeneic BMT for the intended purpose of increasing GVL effects and/or promoting immune responses against infectious agents.
CpG ODN-mediated acceleration of GVHD was dependent on TLR9 ligation of host APCs and host IFNγ production but independent of host NK cells or host IL-12 or IL-6 production or TLR9 ligation of donor BM APCs. These data are consistent with reports implicating host APCs as being critical in optimal GVHD generation [42] [43] [44] [45] [46] [47] . CpG
ODNs given on day 0 and +7 or a single injection on day +7 were sufficient to accelerate GVHD mortality, the latter potentially due to a second burst of proinflammatory cytokine production, resulting in sustained expansion of effector T cells (data not shown). The effect of CpG ODNs on driving effector T cell expansion was supported by day 14 GFP + effector imaging indicated markedly increased donor T cell number in lymphoid and nonlymphoid organs. Moreover, the GVHD acceleration was potent since CpG ODNs only.
For given allogeneic TCD donor BM was not due to poor engraftment (data not shown).
The results implicating host APCs as being a critical target for CpG ODNmediated GVHD acceleration were not so surprising given the data incriminating host
APCs as the major target of GVHD effector T cells [42] [43] [44] [45] [46] [47] . However, the results implicating donor APCs as the target for CpG ODN-mediated BM graft rejection were unexpected.
Because CpG ODN is referred to as the universal vaccine due to the potent adjuvant-like, non-specific immune stimulus delivered to the recipient's innate immune system 13, 14, 18, [48] [49] [50] [51] [52] , we predicted that CpG ODN signaling of host TLR9 would be sufficient to increase rejection. We hypothesized that CpG ODN would ligate host TLR9 resulting in the increased production of the proinflammatory cytokines IL-12, IFNγ, TNFα and IL-6 that would amplify a host anti-donor T cell response sufficient to increase BM rejection regardless of the precise target cell or whether T cell-mediated rejection was the result of direct or indirect alloantigen recognition. Contrary to our expectations, CpG ODN Alternatively, the array of costimulatory molecules induced and upregulated on donor myeloid cells by TLR agonists may provide a more potent signal to rejecting host T cells compared with that induced and upregulated on donor B-lineage cells.
Although these studies were undertaken to discover the mechanism behind CpG ODN-mediated graft rejection, the data identified an important and heretofore, overlooked, role for donor BM APCs in modulating the strength of the rejection process.
The finding that costimulation-deficient B7-1/B7-2 -/-allogeneic BM was far less likely splenocytes (e.g., 5S = 5x10 6 , 25S = 25x10 6 splenocytes). n = 8/group, P ≤ 0.036. B)
Lethally irradiated B6 mice were given BALB/c BM and 5x10 6 or 15x10 6 splenocytes. n = 16-24/group, pool of 2-3 experiments, P ≤ 0.009. C) 1x10 6 or 3x10 6 purified B6 T cells were given to non-irradiated, NK-depleted BALB/c SCID mice. n = 8/group, P < 0.05. A-C) CpG ODNs were given ip to cohorts of mice on days 0, 7, 14, 21 and 28 (100 µg/dose). Recipients were lethally irradiated day -1. A) B6 TLR9 -/-mice were given wild-type BALB/c BM and splenocytes (15x10 6 ). n = 8/group, P = 0.085. B) Wild-type B6 mice were given BALB/c wild-type BM and BALB/c TLR9 -/-splenocytes (15x10 6 ). n only.
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